197 related articles for article (PubMed ID: 37308914)
1. Lenvatinib with or without stereotactic body radiotherapy for hepatocellular carcinoma with portal vein tumor thrombosis: a retrospective study.
Ji X; Xu Z; Sun J; Li W; Duan X; Wang Q
Radiat Oncol; 2023 Jun; 18(1):101. PubMed ID: 37308914
[TBL] [Abstract][Full Text] [Related]
2. Comparison of stereotactic body radiotherapy with and without lenvatinib for advanced hepatocellular carcinoma: a propensity score analysis.
Wang Q; Ji X; Sun J; Li W; Duan X; Zhang A
J Cancer Res Clin Oncol; 2023 Aug; 149(10):7441-7452. PubMed ID: 36952005
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and safety of transarterial chemoembolization combined with lenvatinib, programmed death-1 inhibitor, and iodine-125 seed brachytherapy for hepatocellular carcinoma with portal vein tumor thrombosis.
Lin LW; Yan LY; Ke K; Yang WZ; Lin JQ; Huang N
Brachytherapy; 2023; 22(6):858-871. PubMed ID: 37574351
[TBL] [Abstract][Full Text] [Related]
4. Correlation and efficacy of TACE combined with lenvatinib plus PD-1 inhibitor in the treatment of hepatocellular carcinoma with portal vein tumor thrombus based on immunological features.
Zou X; Xu Q; You R; Yin G
Cancer Med; 2023 May; 12(10):11315-11333. PubMed ID: 36951443
[TBL] [Abstract][Full Text] [Related]
5. Stereotactic body radiotherapy based treatment for hepatocellular carcinoma with extensive portal vein tumor thrombosis.
Shui Y; Yu W; Ren X; Guo Y; Xu J; Ma T; Zhang B; Wu J; Li Q; Hu Q; Shen L; Bai X; Liang T; Wei Q
Radiat Oncol; 2018 Sep; 13(1):188. PubMed ID: 30253783
[TBL] [Abstract][Full Text] [Related]
6. Transarterial chemoembolization plus lenvatinib versus transarterial chemoembolization plus sorafenib as first-line treatment for hepatocellular carcinoma with portal vein tumor thrombus: A prospective randomized study.
Ding X; Sun W; Li W; Shen Y; Guo X; Teng Y; Liu X; Zheng L; Li W; Chen J
Cancer; 2021 Oct; 127(20):3782-3793. PubMed ID: 34237154
[TBL] [Abstract][Full Text] [Related]
7. Stereotactic body radiotherapy plus transcatheter arterial chemoembolization for inoperable hepatocellular carcinoma patients with portal vein tumour thrombus: A meta-analysis.
Zhang XF; Lai L; Zhou H; Mo YJ; Lu XQ; Liu M; Lu YX; Hou EC
PLoS One; 2022; 17(5):e0268779. PubMed ID: 35594278
[TBL] [Abstract][Full Text] [Related]
8. Induction therapy with hepatic arterial infusion chemotherapy enhances the efficacy of lenvatinib and pd1 inhibitors in treating hepatocellular carcinoma patients with portal vein tumor thrombosis.
Fu Y; Peng W; Zhang W; Yang Z; Hu Z; Pang Y; Hu D; Chen J; Wang J; Zhou Z; Xu L; Chen M; Zhang Y
J Gastroenterol; 2023 Apr; 58(4):413-424. PubMed ID: 36894804
[TBL] [Abstract][Full Text] [Related]
9. Stereotactic body radiotherapy versus intensity-modulated radiotherapy for hepatocellular carcinoma with portal vein tumor thrombosis.
Li LQ; Zhou Y; Huang Y; Liang P; Liang SX; Su TS
Hepatol Int; 2021 Jun; 15(3):630-641. PubMed ID: 33818714
[TBL] [Abstract][Full Text] [Related]
10. Stereotactic Body Radiotherapy Combined With Lenvatinib With or Without PD-1 Inhibitors as Initial Treatment for Unresectable Hepatocellular Carcinoma.
Wang Q; Ji X; Sun J; Zhang A; Jia J; Zhang T; Li W; Duan X
Int J Radiat Oncol Biol Phys; 2024 Apr; ():. PubMed ID: 38583495
[TBL] [Abstract][Full Text] [Related]
11. Evaluating the Benefits of TACE Combined with Lenvatinib Plus PD-1 Inhibitor for Hepatocellular Carcinoma with Portal Vein Tumor Thrombus.
Zou X; Xu Q; You R; Yin G
Adv Ther; 2023 Apr; 40(4):1686-1704. PubMed ID: 36805422
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and safety of anti-PD-1 monotherapy
Liu Q; Li R; Li L; Wang G; Ji S; Zheng X; Jia X; Tao H; Hu Y
Ther Adv Med Oncol; 2023; 15():17588359231206274. PubMed ID: 37885459
[TBL] [Abstract][Full Text] [Related]
13. A multicenter prospective study of TACE combined with lenvatinib and camrelizumab for hepatocellular carcinoma with portal vein tumor thrombus.
Li X; Ding X; Liu M; Wang J; Sun W; Teng Y; Xu Y; Wu H; Li W; Zhou L; Chen J
Cancer Med; 2023 Aug; 12(16):16805-16814. PubMed ID: 37387602
[TBL] [Abstract][Full Text] [Related]
14. Safety and Efficacy of Liver-Directed Radiotherapy in Combination With Lenvatinib for Hepatocelluar Carcinoma With Macroscopic Tumor Thrombosis.
Yu JI; Kang W; Yoo GS; Goh MJ; Sinn DH; Gwak GY; Paik YH; Choi MS; Lee JH; Koh KC; Paik SW; Hong JY; Lim HY; Park B; Park HC
Front Oncol; 2022; 12():888755. PubMed ID: 35646674
[TBL] [Abstract][Full Text] [Related]
15. Portal vein tumour thrombosis radiotherapy improves the treatment outcomes of immunotherapy plus bevacizumab in hepatocellular carcinoma: a multicentre real-world analysis with propensity score matching.
Tang C; He Q; Feng J; Liao Z; Peng Y; Gao J
Front Immunol; 2023; 14():1254158. PubMed ID: 37928530
[TBL] [Abstract][Full Text] [Related]
16. Transarterial radioembolization versus tyrosine kinase inhibitor in hepatocellular carcinoma with portal vein thrombosis.
Hur MH; Cho Y; Kim DY; Lee JS; Kim GM; Kim HC; Sinn DH; Hyun D; Lee HA; Seo YS; Lee IJ; Park JW; Kim YJ
Clin Mol Hepatol; 2023 Jul; 29(3):763-778. PubMed ID: 37254488
[TBL] [Abstract][Full Text] [Related]
17. Comparison of stereotactic body radiation therapy with and without sorafenib as treatment for hepatocellular carcinoma with portal vein tumor thrombosis.
Que J; Wu HC; Lin CH; Huang CI; Li LC; Ho CH
Medicine (Baltimore); 2020 Mar; 99(13):e19660. PubMed ID: 32221093
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and safety of transarterial chemoembolization-lenvatinib sequential therapy for the treatment of hepatocellular carcinoma with portal vein tumor thrombus: a retrospective study.
Chen R; Li Y; Song K; Li L; Shen C; Ma P; Wang Z
J Gastrointest Oncol; 2022 Apr; 13(2):780-786. PubMed ID: 35557575
[TBL] [Abstract][Full Text] [Related]
19. Effectiveness of stereotactic body radiotherapy for portal vein tumor thrombosis in patients with hepatocellular carcinoma and underlying chronic liver disease.
Choi HS; Kang KM; Jeong BK; Jeong H; Lee YH; Ha IB; Song JH
Asia Pac J Clin Oncol; 2021 Jun; 17(3):209-215. PubMed ID: 32757461
[TBL] [Abstract][Full Text] [Related]
20. Effectiveness and Safety of the PD-1 Inhibitor Lenvatinib Plus Radiotherapy in Patients with HCC with Main PVTT: Real-World Data from a Tertiary Centre.
Li G; Zhao Y; Li K; Yang S; Xiang C; Song J; Yang Y; Li G; Dong J
J Hepatocell Carcinoma; 2023; 10():2037-2048. PubMed ID: 37965075
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
